CSTL
Castle Biosciences
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 1
consensus rating "Buy"
Revenue Beats Expectation
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About CSTL
Castle Biosciences, Inc.
A company that develops and commercializes diagnostic and prognostic tests for dermatologic cancers
Biological Technology
09/12/2007
07/25/2019
NASDAQ Stock Exchange
761
12-31
Common stock
505 S. Friendswood Drive, Suite 401, Friendswood, Texas 77546
--
Castle Biosciences, Inc., was incorporated in Delaware on September 12, 2007. The company is a commercial-stage dermatological cancer company dedicated to providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions.
Company Financials
EPS
CSTL has released its 2024 Q4 earnings. EPS was reported at 0.32, versus the expected 0.04, beating expectations. The chart below visualizes how CSTL has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CSTL has released its 2024 Q4 earnings report, with revenue of 86.31M, reflecting a YoY change of 30.54%, and net profit of 9.59M, showing a YoY change of 471.71%. The Sankey diagram below clearly presents CSTL’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
